Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-046994
Filing Date
2025-03-31
Accepted
2025-03-28 18:00:38
Documents
107
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K sabs-20241231.htm   iXBRL 10-K 4387991
2 EX-10.4 sabs-ex10_4.htm EX-10.4 152243
3 EX-19.1 sabs-ex19_1.htm EX-19.1 792
4 EX-21.1 sabs-ex21_1.htm EX-21.1 3154
5 EX-23.1 sabs-ex23_1.htm EX-23.1 3492
6 EX-31.1 sabs-ex31_1.htm EX-31.1 25464
7 EX-31.2 sabs-ex31_2.htm EX-31.2 25422
8 EX-32.1 sabs-ex32_1.htm EX-32.1 10619
9 EX-32.2 sabs-ex32_2.htm EX-32.2 10495
10 GRAPHIC img153703469_0.jpg GRAPHIC 591425
11 GRAPHIC img153703469_1.jpg GRAPHIC 445267
12 GRAPHIC img153703469_2.jpg GRAPHIC 644657
  Complete submission text file 0000950170-25-046994.txt   19792892

Data Files

Seq Description Document Type Size
13 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT sabs-20241231.xsd EX-101.SCH 1942677
110 EXTRACTED XBRL INSTANCE DOCUMENT sabs-20241231_htm.xml XML 2629947
Mailing Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140
Business Address 777 W 41ST ST SUITE 401 MIAMI BEACH FL 33140 305-845-2813
SAB Biotherapeutics, Inc. (Filer) CIK: 0001833214 (see all company filings)

EIN.: 853899721 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-39871 | Film No.: 25788131
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)